| HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade DM Woods, AL Sodré, A Villagra, A Sarnaik, EM Sotomayor, J Weber Cancer immunology research 3 (12), 1375-1385, 2015 | 418 | 2015 |
| Predictors of responses to immune checkpoint blockade in advanced melanoma N Jacquelot, MP Roberti, DP Enot, S Rusakiewicz, N Ternès, S Jegou, ... Nature communications 8 (1), 592, 2017 | 198 | 2017 |
| Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition AS Laino, D Woods, M Vassallo, X Qian, H Tang, M Wind-Rotolo, J Weber Journal for immunotherapy of cancer 8 (1), 2020 | 155 | 2020 |
| The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy D Briere, N Sudhakar, DM Woods, J Hallin, LD Engstrom, R Aranda, ... Cancer Immunology, Immunotherapy 67, 381-392, 2018 | 139 | 2018 |
| The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity DM Woods, K Woan, F Cheng, H Wang, P Perez-Villarroel, C Lee, ... Melanoma research 23 (5), 341-348, 2013 | 132 | 2013 |
| C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. WJ Yoshida T, Ichikawa J, Giuroiu I, Laino AS, Hao Y, Krogsgaard M, Vassallo ... J Immunother Cancer 8 (1), 2020 | 73 | 2020 |
| T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model DM Woods, KV Woan, F Cheng, AL Sodré, D Wang, Y Wu, Z Wang, ... Blood, The Journal of the American Society of Hematology 130 (2), 146-155, 2017 | 71 | 2017 |
| HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics AS Laino, BC Betts, A Veerapathran, I Dolgalev, A Sarnaik, SN Quayle, ... Journal for immunotherapy of cancer 7, 1-16, 2019 | 68 | 2019 |
| Decreased suppression and increased phosphorylated STAT3 in regulatory T cells are associated with benefit from adjuvant PD-1 blockade in resected metastatic melanoma DM Woods, R Ramakrishnan, AS Laino, A Berglund, K Walton, BC Betts, ... Clinical Cancer Research 24 (24), 6236-6247, 2018 | 57 | 2018 |
| Association of tumor microenvironment T-cell repertoire and mutational load with clinical outcome after sequential checkpoint blockade in melanoma E Yusko, M Vignali, RK Wilson, ER Mardis, FS Hodi, C Horak, H Chang, ... Cancer immunology research 7 (3), 458-465, 2019 | 49 | 2019 |
| Rapid expansion of highly functional antigen-specific T cells from patients with melanoma by nanoscale artificial antigen-presenting cells J Ichikawa, T Yoshida, A Isser, AS Laino, M Vassallo, D Woods, S Kim, ... Clinical Cancer Research 26 (13), 3384-3396, 2020 | 34 | 2020 |
| High-parameter single-cell analysis PK Chattopadhyay, AF Winters, WE Lomas III, AS Laino, DM Woods Annual Review of Analytical Chemistry 12 (1), 411-430, 2019 | 34 | 2019 |
| Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes DM Woods, AS Laino, A Winters, J Alexandre, D Freeman, V Rao, ... JCI insight 5 (11), 2020 | 15 | 2020 |
| Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma JS Weber, BA Levinson, AS Laino, AC Pavlick, DM Woods Melanoma research 32 (5), 324-333, 2022 | 11 | 2022 |
| A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance A Mitra, B Thompson, A Strange, CM Amato, M Vassallo, I Dolgalev, ... Clinical Cancer Research 29 (20), 4242-4255, 2023 | 7 | 2023 |
| Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma NI Khushalani, M Vassallo, JD Goldberg, Z Eroglu, Y Kim, B Cao, ... Journal for Immunotherapy of Cancer 10 (11), 2022 | 4 | 2022 |
| CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy B Thompson, A Strange, CM Amato, J Hester-McCullough, AA Sarnaik, ... The Journal of Immunology 211 (5), 735-742, 2023 | | 2023 |
| PhenoComb: a discovery tool to assess complex phenotypes in high-dimensional single-cell datasets DMW Paulo E P Burke, Ann Strange, Emily Monk, Brian Thompson, Carol M Amato Bioinformatics Advances 2 (1), 2022 | | 2022 |
